Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

29 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Circulating miR34a levels as a potential biomarker in the follow-up of Ewing sarcoma.
Sciandra M, De Feo A, Parra A, Landuzzi L, Lollini PL, Manara MC, Mattia G, Pontecorvi G, Baricordi C, Guerzoni C, Bazzocchi A, Longhi A, Scotlandi K. Sciandra M, et al. Among authors: guerzoni c. J Cell Commun Signal. 2020 Sep;14(3):335-347. doi: 10.1007/s12079-020-00567-2. Epub 2020 Jun 5. J Cell Commun Signal. 2020. PMID: 32504411 Free PMC article.
CD99 triggering in Ewing sarcoma delivers a lethal signal through p53 pathway reactivation and cooperates with doxorubicin.
Guerzoni C, Fiori V, Terracciano M, Manara MC, Moricoli D, Pasello M, Sciandra M, Nicoletti G, Gellini M, Dominici S, Chiodoni C, Fornasari PM, Lollini PL, Colombo MP, Picci P, Cianfriglia M, Magnani M, Scotlandi K. Guerzoni C, et al. Clin Cancer Res. 2015 Jan 1;21(1):146-56. doi: 10.1158/1078-0432.CCR-14-0492. Epub 2014 Dec 11. Clin Cancer Res. 2015. PMID: 25501132
Targeting CD99 Compromises the Oncogenic Effects of the Chimera EWS-FLI1 by Inducing Reexpression of Zyxin and Inhibition of GLI1 Activity.
Balestra T, Manara MC, Laginestra MA, Pasello M, De Feo A, Bassi C, Guerzoni C, Landuzzi L, Lollini PL, Donati DM, Negrini M, Magnani M, Scotlandi K. Balestra T, et al. Among authors: guerzoni c. Mol Cancer Ther. 2022 Jan;21(1):58-69. doi: 10.1158/1535-7163.MCT-21-0189. Epub 2021 Oct 19. Mol Cancer Ther. 2022. PMID: 34667115
Process development of a human recombinant diabody expressed in E. coli: engagement of CD99-induced apoptosis for target therapy in Ewing's sarcoma.
Moricoli D, Carbonella DC, Dominici S, Fiori V, Balducci MC, Guerzoni C, Manara MC, Pasello M, Laguardia ME, Cianfriglia M, Scotlandi K, Magnani M. Moricoli D, et al. Among authors: guerzoni c. Appl Microbiol Biotechnol. 2016 May;100(9):3949-63. doi: 10.1007/s00253-015-7226-5. Epub 2015 Dec 21. Appl Microbiol Biotechnol. 2016. PMID: 26685854
NVP-BEZ235 as a new therapeutic option for sarcomas.
Manara MC, Nicoletti G, Zambelli D, Ventura S, Guerzoni C, Landuzzi L, Lollini PL, Maira SM, García-Echeverría C, Mercuri M, Picci P, Scotlandi K. Manara MC, et al. Among authors: guerzoni c. Clin Cancer Res. 2010 Jan 15;16(2):530-40. doi: 10.1158/1078-0432.CCR-09-0816. Epub 2010 Jan 12. Clin Cancer Res. 2010. PMID: 20068094
A Quinoline-Based DNA Methyltransferase Inhibitor as a Possible Adjuvant in Osteosarcoma Therapy.
Manara MC, Valente S, Cristalli C, Nicoletti G, Landuzzi L, Zwergel C, Mazzone R, Stazi G, Arimondo PB, Pasello M, Guerzoni C, Picci P, Nanni P, Lollini PL, Mai A, Scotlandi K. Manara MC, et al. Among authors: guerzoni c. Mol Cancer Ther. 2018 Sep;17(9):1881-1892. doi: 10.1158/1535-7163.MCT-17-0818. Epub 2018 Jun 29. Mol Cancer Ther. 2018. PMID: 29959201
CD99 suppresses osteosarcoma cell migration through inhibition of ROCK2 activity.
Zucchini C, Manara MC, Pinca RS, De Sanctis P, Guerzoni C, Sciandra M, Lollini PL, Cenacchi G, Picci P, Valvassori L, Scotlandi K. Zucchini C, et al. Among authors: guerzoni c. Oncogene. 2014 Apr 10;33(15):1912-21. doi: 10.1038/onc.2013.152. Epub 2013 May 6. Oncogene. 2014. PMID: 23644663
29 results